AR006569A1 - Derivados de acidos carboxilicos, medicamentos que contienen estos compuestos, su utilizacion y procedimientos para su preparacion - Google Patents

Derivados de acidos carboxilicos, medicamentos que contienen estos compuestos, su utilizacion y procedimientos para su preparacion

Info

Publication number
AR006569A1
AR006569A1 ARP970101395A ARP970101395A AR006569A1 AR 006569 A1 AR006569 A1 AR 006569A1 AR P970101395 A ARP970101395 A AR P970101395A AR P970101395 A ARP970101395 A AR P970101395A AR 006569 A1 AR006569 A1 AR 006569A1
Authority
AR
Argentina
Prior art keywords
derivatives
compounds
preparation
carboxylic acids
procedures
Prior art date
Application number
ARP970101395A
Other languages
English (en)
Original Assignee
Thomae Gmbh Dr K
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomae Gmbh Dr K filed Critical Thomae Gmbh Dr K
Publication of AR006569A1 publication Critical patent/AR006569A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/46Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • C07D211/58Nitrogen atoms attached in position 4

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Derivados de ácidos carboxílicos de la fórmula general (I) en la que Ra hasta Rc, A, B, D, E y X1 hasta X3 están definidos como la reivindicacion 1, asus tautómeros, a sus estereoisómeros, inclusive sus mezlcas y a sus sales, especialmente sus sales fisiológicamente compatibles con ácidos o basesinorgánicos u orgánicos, que tienen valiosas propiedades farmacológicas, preferiblemente efectos inhibidores de la agregación, a medicamentos quecontienen estos compuestos, a su utilización y a procedimientos para su preparación.
ARP970101395A 1996-04-10 1997-04-09 Derivados de acidos carboxilicos, medicamentos que contienen estos compuestos, su utilizacion y procedimientos para su preparacion AR006569A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19614204A DE19614204A1 (de) 1996-04-10 1996-04-10 Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung

Publications (1)

Publication Number Publication Date
AR006569A1 true AR006569A1 (es) 1999-09-08

Family

ID=7790922

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970101395A AR006569A1 (es) 1996-04-10 1997-04-09 Derivados de acidos carboxilicos, medicamentos que contienen estos compuestos, su utilizacion y procedimientos para su preparacion

Country Status (9)

Country Link
US (1) US5994356A (es)
EP (1) EP0892783A1 (es)
JP (1) JP2000508307A (es)
AR (1) AR006569A1 (es)
AU (1) AU2636897A (es)
CO (1) CO4560551A1 (es)
DE (1) DE19614204A1 (es)
WO (1) WO1997037975A1 (es)
ZA (1) ZA973002B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6964974B2 (en) * 2000-09-08 2005-11-15 Hoffmann-La Roche Inc. 2,3-oxidosqualene-lanosterol cyclase inhibitors
CA2437118A1 (en) * 2001-02-09 2002-08-22 Merck & Co., Inc. 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders
CA2463626C (en) * 2001-10-17 2011-05-24 Schering Corporation Piperidine- and piperazineacetamines as 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
US7390813B1 (en) 2001-12-21 2008-06-24 Xenon Pharmaceuticals Inc. Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents
US20050119251A1 (en) * 2001-12-21 2005-06-02 Jian-Min Fu Nicotinamide derivatives and their use as therapeutic agents
WO2004048334A1 (en) * 2002-11-26 2004-06-10 Pfizer Products Inc. Phenyl substituted piperidine compounds for use as ppar activators
PE20040769A1 (es) * 2002-12-18 2004-11-06 Schering Corp Derivados de piperidina utiles como antagonisas ccr5
TW200508224A (en) 2003-02-12 2005-03-01 Bristol Myers Squibb Co Cyclic derivatives as modulators of chemokine receptor activity
US7754711B2 (en) * 2003-07-30 2010-07-13 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
US7759348B2 (en) * 2003-07-30 2010-07-20 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
ES2568769T3 (es) * 2003-07-30 2016-05-04 Xenon Pharmaceuticals Inc. Derivados de piperazina y su uso como agentes terapéuticos
JP4831577B2 (ja) * 2003-07-30 2011-12-07 ゼノン・ファーマシューティカルズ・インコーポレイテッド ピリダジン誘導体および治療剤としての用途
SE0401971D0 (sv) * 2004-08-02 2004-08-02 Astrazeneca Ab Piperidne derivatives
WO2006034279A1 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
CN101083982A (zh) 2004-09-20 2007-12-05 泽农医药公司 用于治疗硬脂酰CoA去饱和酶介导的疾病的杂环衍生物
CN101084207A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为硬脂酰CoA去饱和酶抑制剂的用途
TW200626154A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
TW200626155A (en) * 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
AR051095A1 (es) * 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso comoinhibidores de la estearoil-coa desaturasa
AU2005329423A1 (en) * 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
BRPI0515478A (pt) * 2004-09-20 2008-07-22 Xenon Pharmaceuticals Inc derivados heterocìclicos e seu uso como mediadores de estearoil-coa-desaturase
BRPI0611187A2 (pt) * 2005-06-03 2010-08-24 Xenon Pharmaceuticals Inc derivados aminotiazàis como inibidores da estearoil-coa desaturase humana
AU2006264651A1 (en) * 2005-06-30 2007-01-11 Prosidion Limited G-protein coupled receptor agonists
GB0514811D0 (en) * 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
US20070197590A1 (en) * 2006-01-31 2007-08-23 Demong Duane E Substituted dipiperidine ccr2 antagonists
US20170327457A1 (en) 2014-09-09 2017-11-16 Bristol-Myers Squibb Company Phenyl-(aza)cycloalkyl carboxylic acid gpr120 modulators
WO2024072930A1 (en) * 2022-09-30 2024-04-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dopamine d3/d2 receptor partial agonists for the treatment of neuropsychiatric disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4127404A1 (de) * 1991-08-19 1993-02-25 Thomae Gmbh Dr K Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5227490A (en) * 1992-02-21 1993-07-13 Merck & Co., Inc. Fibrinogen receptor antagonists
DE4241632A1 (de) * 1992-12-10 1994-06-16 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5652242A (en) * 1993-03-29 1997-07-29 Zeneca Limited Heterocyclic derivatives
DE4326344A1 (de) * 1993-08-05 1995-02-09 Thomae Gmbh Dr K Carbonamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung

Also Published As

Publication number Publication date
CO4560551A1 (es) 1998-02-10
JP2000508307A (ja) 2000-07-04
EP0892783A1 (de) 1999-01-27
DE19614204A1 (de) 1997-10-16
US5994356A (en) 1999-11-30
WO1997037975A1 (de) 1997-10-16
AU2636897A (en) 1997-10-29
ZA973002B (en) 1998-10-09

Similar Documents

Publication Publication Date Title
AR006569A1 (es) Derivados de acidos carboxilicos, medicamentos que contienen estos compuestos, su utilizacion y procedimientos para su preparacion
MX9306303A (es) Derivados de acidos carboxilicos, medicamentos que contienen estos compuestos y procedimientos para su preparacion.
MX9307781A (es) Derivados de acidos carboxilicos, medicamentos que contienen estos compuestos y procedimientos para su preparacion.
MX9305566A (es) Derivados de urea ciclicos, medicamentos que contienen estos compuestos y procedimientos para su preparacion.
ECSP055747A (es) Antagonistas de cgrp elegidos, procedimiento para su preparación, así como su empleo como medicamentos
UY26903A1 (es) Heterociclos bicíclicos, medicamentos que contienen estos compuestos, su empleo y procedimientos para su preparación
AR008878A1 (es) Antagonistas del receptor de vitronectina, un metodo para su preparacion, una composicion farmaceutica que los contiene y el uso de las mismas para la preparacion de un medicamento.
UY26659A1 (es) Heterociclos bicíclicos, medicamentos que contienen estos compuestos, su empleo y procedimientos para su preparación
MX9303466A (es) Derivados de bifenilo, medicamentos que contienen estos compuestos y procedimiento para su preparacion.
AR027113A1 (es) Piperidinas sustiutidas, medicamentos que contienen estos compuestos y procedimiento par su preparacion
MX9207334A (es) Acidos nucleicos peptidicos y formulacion farma- ceutica que los contiene
AR022906A1 (es) Amidas de aminoacidos modificadas, medicamentos que contienen estos compuestos y procedimiento para su preparacion
AR029175A1 (es) Derivados 2-amino-fenilpurina, un proceso para su preparacion, composicion farmaceutica que los comprende, y el uso de los mismos para la preparacion de un medicamento
BR0116266A (pt) Derivados de quinazolina, composições farmacêuticas contendo estes compostos, seu uso e processos para sua preparação
PA8548001A1 (es) Derivados aromaticos de acidos dicarboxilicos
ECSP034883A (es) Amidas de acidos antranilicos con cadena lateral de heteroarilsulfonilo, procedimiento para su preparacion, su empleo como medicamento o agente de diagnostico, asi como preparados farmaceuticos que las contienen
AR019853A1 (es) Derivado del acido 3-aril-2-hidroxipropionico, proceso e intermediario para su preparacion, formulaciones farmaceuticas, uso de dicho compuesto en laelaboracion de un medicamento, metodo para la profilaxis y/o tratamiento de trastornos clinicos asociados con la resistencia a la insulina, y formulaci
NO903911L (no) Fremgangsmaate for fremstilling av 4-hydroksytetrahydropyran-2-on og de tilsvarende dihydroksykarboksylsyrederivater, salter og estere, deres anvendelse som legemidler, farmasoeytiske og forprodukter.
ES2045182T3 (es) Substancias fisiologicamente activas, un proceso para la preparacion de las mismas y composiciones farmaceuticas que las contienen.
BR0015147A (pt) Ciclopropanos como cgrp-antagonistas, medicamentos contendo os ditos compostos e processo para a produção dos mesmos
MX9302459A (es) Derivados imino ciclicos, medicamentos que contienen estos compuestos y procedimientos para su preparacion.
BR0014826A (pt) Imidazo-3-il-aminas bicìclicas, procedimento de sua preparação e medicamentos que as contêm
AR005102A1 (es) Compuestos derivados de octahidro-pirrolo [1,2-a]-pirazina 2,7-sustituidos, composiciones farmaceuticas y uso de dichos compuestos para la fabricacion deun medicamento.
ES2153842T3 (es) Derivados de 3-oxo-pirido(1,2-a-)bencimidazol-4-carboxilo y de 4-oxo-azepino(1,2-a)bencimidazol-5-carboxilo utiles en el tratamiento de enfermedades del sistema nervioso central.
ES2158309T3 (es) Fenilamidinas sustituidas, medicamentos que contienen a estos compuestos y procedimiento para su preparacion.